Imipenem and Meropenem: Comparison of In Vitro Activity, Pharmacokinetics, Clinical Trials and Adverse Effects

Simple item page
dc.contributor.authorZhanel, George G
dc.contributor.authorSimor, Andrew E
dc.contributor.authorVercaigne, Lavern
dc.contributor.authorMandell, Lionell
dc.contributor.authorthe Canadian Carbapenem Discussion Group,
dc.date.accessioned2016-06-09T16:19:22Z
dc.date.available2016-06-09T16:19:22Z
dc.date.issued1998-1-1
dc.date.updated2016-06-07T07:02:58Z
dc.description.abstractOBJECTIVE: To compare and contrast imipenem and meropenem in terms of in vitro activity, pharmacokinetics, clinical efficacy and adverse effects.DATA SELECTION: MEDLINE search from 1975 to 1997 and follow-up of references.DATA EXTRACTION: Clinical trials comparing imipenem with meropenem, or either imipenem or meropenem with standard therapy in the treatment of serious infections were selected.DATA SYNTHESIS: Imipenem, the first carbapenem, was first marketed in 1987; meropenem was introduced to the market in 1996. In general, imipenem is more active against Gram-positive cocci while meropenem is more active against Gram-negative bacilli. The agents display similar pharmacokinetics. Clinical studies in patients with serious infections (intra-abdominal infection, respiratory infection, septicemia, febrile neutropenia) report similar bacteriological and clinical cure rates with imipenem and meropenem. Meropenem is approved for the treatment of bacterial meningitis, whereas imipenem is not. Adverse effects are similar.CONCLUSIONS: Current literature supports the use of imipenem at a dose of 500 mg every 6 h and meropenem at 1 g every 8 h for the treatment of severe infections. For the treatment of serious infections, imipenem (500 mg every 6 h or 2 g/day [$98/day]) is more economical than meropenem (1 g every 8 h or 3 g/day [$142/day]) based on acquisition cost.
dc.description.versionPeer Reviewed
dc.identifier.citationGeorge G Zhanel, Andrew E Simor, Lavern Vercaigne, Lionell Mandell, and the Canadian Carbapenem Discussion Group, “Imipenem and Meropenem: Comparison of In Vitro Activity, Pharmacokinetics, Clinical Trials and Adverse Effects,” Canadian Journal of Infectious Diseases, vol. 9, no. 4, pp. 215-228, 1998. doi:10.1155/1998/831425
dc.identifier.urihttp://dx.doi.org/10.1155/1998/831425
dc.identifier.urihttp://hdl.handle.net/1993/31463
dc.language.rfc3066en
dc.rightsopen accessen_US
dc.rights.holderCopyright © 1998 Hindawi Publishing Corporation. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
dc.titleImipenem and Meropenem: Comparison of In Vitro Activity, Pharmacokinetics, Clinical Trials and Adverse Effects
dc.typeJournal Article
Files
Original bundle
Now showing 1 - 2 of 2
Thumbnail Image
Name:
CJIDMM.1998.831425.xml
Size:
11.95 KB
Format:
Extensible Markup Language
Description:
Download
Thumbnail Image
Name:
CJIDMM.1998.831425.pdf
Size:
550.85 KB
Format:
Adobe Portable Document Format
Description:
Download
License bundle
Now showing 1 - 1 of 1
Thumbnail Image
Name:
license.txt
Size:
2.24 KB
Format:
Item-specific license agreed to upon submission
Description:
Download
Collections
University of Manitoba Scholarship
Rady Faculty of Health Sciences Scholarly Works